Cancer arises from the accumulation of genetic alterations, which can lead to the production of mutant proteins not expressed by normal cells. These mutant proteins can be processed and presented on the cell surface by major histocompatibility complex molecules as neoepitopes, allowing CD8
INTRODUCTION
Recent insights from animal studies, translational research, and correlative clinical data have highlighted the importance of the immune system as a therapeutic target for cancer treatment (1) (2) (3) (4) . Among the most promising are immunotherapies aimed at exploiting and co-opting the host's adaptive immune system, particularly cytotoxic CD8 + T cells (2, (5) (6) (7) (8) . Currently, several approaches to targeting tumors with specific immune effectors are beginning to bear fruit, including the use of (i) immunomodulatory monoclonal antibodies blocking inhibitory receptor signaling in endogenous antitumor CD8 + 
T cells, (ii) expanded tumor-infiltrating lymphocytes (TILs), (iii) T cell receptor (TCR)-engineered T cells (TCR-T), and (iv) chimeric antigen receptor (CAR)-expressing T cells (9-19).
Although immunomodulatory therapies have shown clinical utility in some adult solid tumors, especially those with higher mutation burdens (20) (21) (22) (23) , attempts to identify tumor-reactive T cell responses against identified mutations have had a relatively low success rate for any given mutation, with only about 2% eliciting a measurable response in patients either functionally or by tetramer staining. This has led to the hypothesis that qualitative features of the mutations, including whether they contain substantial non-self-sequences or homology to a pathogen-associated epitope, influence the endogenous T cell response and efficacy of checkpoint blockade immunotherapies (24, 25) .
In parallel to the development of immune checkpoint blockade (ICB), CAR and TCR-T approaches that engineer the patient's own T cells with a single specificity to target the tumor have shown efficacy. These approaches target tumor-associated antigens, such as CD19 in B cell malignancies, or tumor-specific antigens, such as the H3-K27M mutation in gliomas (26) (27) (28) . Identifying tumor-specific mutations provides an advantage over targeting tumor-associated antigens by limiting collateral losses, such as the B cell aplasia observed after CD19 CAR therapy. To date, these approaches have targeted single antigens, demonstrating that a monoclonal immune response is competent for tumor control under appropriate conditions. The identification of additional high-quality targets is a major focus for cell-based therapy research.
Many of the aforementioned studies were carried out in adult solid tumors with high mutation rates (29, 30) , leaving open the question of whether low mutation burden tumors contain correspondingly poor endogenous T cell responses, a view loosely supported by the observation that checkpoint blockade has generally not been as successful in these tumors (21) . This question has particular relevance for pediatric tumors, which generally exhibit markedly fewer somatic mutations. Although recent studies using immunomodulatory therapies in pediatric patients with neuroblastoma appear promising (31, 32) , these therapies are hypothesized to enlist endogenous natural killer cells; thus, further research is needed to establish whether antitumor CD8 + T cell responses are also present in childhood cancers. In this study, we aimed to establish the endogenous CD8 + T cell response from pediatric patients with acute lymphoblastic leukemia (ALL), which, on average, has far fewer nonsynonymous mutations than other tumor types (33) , and to identify candidate tumor-specific mutations that may be targetable by TCR-T cells. We hypothesized that although leukemias contain lower mutational burdens, the neoantigens that arise in this tumor type might serve as functional targets capable of inducing antitumor T cell responses (34) .
RESULTS

Identification of putative neoepitopes in pediatric ALL
To identify putative patient-specific cancer neoantigens ( fig. S1 , A to C), we detected somatically acquired genetic alterations in the tumor via high-throughput genomic sequencing of diagnostic biopsies and matched germline tissue obtained from a cohort of pediatric patients (table S1) with ALL. Tumor samples were also subjected to mRNA sequencing, which was used to determine human leukocyte antigen (HLA) haplotype and confirm the expression of HLA class I genes within the tumor milieu (consisting of tumor, monocytic, and T cells; table S2). Samples from patients with HLA-A genes exhibiting lower fragments per kilobase of transcript per million mapped reads (FPKM) values were also subjected to flow cytometric analysis to confirm that proteins (HLA-A30 and HLA-A2) were also expressed on the surface of the tumor cells used for sequencing ( fig. S1D ).
Using patient-specific HLA class I types inferred from mRNA sequencing, we screened tumor-specific somatic missense mutations and gene fusions for their potential to generate neoepitopes (i.e., neoantigens predicted to bind patient-specific HLA proteins). We classified the binding of peptides to HLA alleles as strong putative neoepitopes if their predicted binding affinity [median inhibitory concentration (IC 50 )] was below 150 nM, as intermediate to weak putative neoepitopes if their IC 50 was between 150 and 500 nM, and as putative nonbinders if their IC 50 was greater than 500 nM. Although the number of mutations in our cohort was low in comparison to other cancer types (35) , we detected between 5 and 28 predicted nonamer neoepitopes per patient (fig. S1B), with an average of 8 strong nonamer neoepitopes (range, 2 to 14) and 6 intermediate nonamer neoepitopes (range, 3 to 14; fig. S1C and table S3) per patient. Furthermore, we predicted epitopes spanning the fusion junction in three of the four patients with detected ETV6-RUNX1 genomic fusions in their tumor biopsies. These mutations were of particular interest because similar fusions occur across multiple patients with distinct HLA haplotypes (36) . Previous studies on cancer patients with melanoma (4, 6, 37) and non-small cell lung carcinoma (21) have identified T cell responses by tetramer or functional assays, but only a small fraction (0.05 to 2%) of the putative neoepitopes tested were found to have elicited a detectable response. Although there is a lower mutational burden in ALL compared to these solid tumors, we hypothesized that this might result in a greater frequency of responsive CD8 + T cells due to the limited number of tumor-specific epitopes available for the immune system to target. To test whether CD8 + T cells within the TILs were responsive to mutated neoepitopes directly ex vivo, we engineered five artificial antigen-presenting cells (aAPCs), each of which expressed a single patient-specific HLA ( fig. S3 ). Focusing on the three patients with the highest frequency of CD8 + T cells, we pulsed the HLA-specific aAPCs with synthetic 15 amino acid peptides that corresponded to the predicted neoepitopes, cocultured them with isolated CD8 + TILs, and monitored for the production of interferon- (IFN) and tumor necrosis factor- (TNF). To control for potential background noise and nonspecific stimulation, we calculated patients' CD8 + T cell cytokine production in the presence of putative patient-specific tumor neoantigens relative to responses to an irrelevant peptide. In addition, we stimulated isolated CD8 + T cells with SEB (staphylococcal enterotoxin B) as a positive control to determine the maximal response rate of these cells and normalized subsequent analyses to this maximum. All three tested peptides in patient ERG009 (two restricted by B*18:01 and one restricted by A*30:02) generated robust responses to peptide-aAPC stimulation, totaling more than 30% of the SEB response (Fig. 1A) . Similarly, the two A*02:01-binding peptides tested with A*02:01 aAPCs for patient ETV001 generated responses (Fig. 1A) . Last, the five peptides for ETV078 all generated responses above background, but the magnitude of the response was relatively low. In summary, all three patients exhibited CD8
+ T cell cytokine production in response to specific peptide stimulation, indicating that the predicted neoepitopes restricted by the patients' HLAs were generating endogenous responses.
Given the unexpectedly high rate of neoantigen-specific responses, we expanded our analyses to include direct stimulation of the bone marrow without the use of aAPCs or purification of the CD8 + T cells, which allowed us to test more neoantigens across a larger number of patients. Freshly processed autologous bone marrow cells (consisting of tumor, APCs, CD8 + T cells, and other cell types and products in the local tumor milieu) were pulsed with synthetic 15 amino acid peptides to monitor the endogenous response of the CD8 + T cells. Figure 1B shows the representative gating strategy from one pediatric ALL patient sample that was used to identify cytokine-producing and degranulating (CD107a/b + ) neoantigenspecific CD8 + TILs. All six patients responded to at least one neoantigenic peptide in this assay, with relatively high rates of reactivity (ranging from ~6 to ~59%) among the total CD8 + TIL population (Fig. 1C) . These analyses identified a spectrum of reactivities by CD8 + TILs ranging from moderate cumulative cytokine responses observed for ERG016 and ETV001 to intermediate responses detected for ERG009 and ETV085 and to strong responses measured for ETV078 and ETV084 (Fig. 1C) . For ERG016, ~15% of the responding CD8 + TILs displayed reactivity toward four of six putative mutant neoantigens, and for ETV001, ~15 and ~6% of the responding CD8 + TILs displayed reactivity toward four of six and four of four single patient-specific HLA molecule and pulsed with anti-human CD28/CD49d (1 g/ml) and either 1 M indicated 15-mer peptide or SEB (100 g/ml). Cytokine production by CD8 + TILs was subsequently measured by intracellular cytokine staining (ICS putative mutant neoantigens, respectively (Fig. 1D ). Among the intermediate responders, CD8 + TIL reactivity for ERG009 and ETV085 was mounted against two of two and eight of eight putative neoantigens, which accounted for ~36 and ~37% of the maximal CD8 + TIL cytokine response, respectively. In addition, for ETV078 and ETV084, ~56 and ~59% of the responding CD8 + TILs were reactive against 7 of 10 and 6 of 23 (only six neoantigens were tested in the assay) putative mutant neoantigens, respectively (Fig. 1D ). Of the 36 putative neoantigens tested in our studies, 31 were found to be immunogenic and capable of inducing robust cytokine responses (Fig. 1, C and D) . To determine whether similar responses would be observed at lower concentrations of neoantigen, where recognition of fewer peptide-major histocompatibility complexes (MHCs) may limit reactivity, we used serial dilutions of mutated peptides to monitor the response of CD8 + T cells to peptide-pulsed autologous bone marrow cells. Several neoantigens elicited reactive CD8 + T cell responses at nanomolar (e.g., PLCD3, EEF1A2, BTBD16, PCNXL2, and PRRC2B) and 100 pM (e.g., AHNAK, AZI1, CD101, FAM157B, SPIRE1, and TMEM104) concentrations (Fig. 1E ).
ETV001
To confirm that the results against exogenously presented peptides were not an artifact of exogenous peptide stimulation and mirrored the responses that would be seen against cells processing and presenting endogenous neoantigens, we used three additional approaches [shown in schematic for tandem minigenes (TMGs) in (Fig. 2D ) and expressing patient-specific HLAs. In both assays, CD8 + T cell reactivity was greater against mutant versus wild-type peptide-encoding TMGs (Fig. 2 , B, C, and E). To test whether healthy individuals also have comparable frequencies of neoantigen-reactive T cells, CD8 + T cells were enriched from healthy adult donor peripheral blood mononuclear cells and cocultured with the mRNA-transfected tumor cells from three patients, and cytokine production was measured by ICS. In all cases, the CD8 + T cell response from healthy donors was negligible against both wild-type and mutant mRNA-transfected tumor cells ( fig. S4 ).
To further validate that the CD8 + TILs specifically recognized putative neoepitopes expressed by unmanipulated autologous tumor cells, we sorted purified CD19 + tumor cells and cocultured them with sorted CD8 + T cells from the diagnostic ALL specimens of two patients (ERG009 and ETV078; see Materials and Methods) with high frequencies of CD8 + T cells and a strong putative neoepitope that could be targeted ( fig. S1 and table S3). Following well-established protocols (38) (39) (40) (41) for expanding TILs and generating T cell lines driven by endogenously presented antigens, we cultured the sorted endogenous CD8 + T cells with either aAPCs expressing patient-specific HLAs (negative control; non-neoantigen expressing targets) or autologous tumor cells. We then constructed peptide-MHC tetramers corresponding to neoantigens identified as strong binders (table S3) and likely to be immunogenic for these patients and analyzed for the presence of neoepitope-specific CD8 + T cells after 21 days of coculturing. A control tetramer for patient ERG009 was used, containing an irrelevant (but HLA-stabilizing) peptide, whereas the "parent" tetramer was used as a control in patient ETV078, containing the endogenous, nonmutated peptide (see Materials and Methods and table S4). For both patients, cocultures containing autologous tumor cells resulted in a greater expansion of tetramer-positive neoepitopespecific CD8 + T cells when compared to the cocultures containing aAPCs (Fig. 2F) . Collectively, these findings demonstrate that tumor neoantigens are processed and presented by the tumors present in pediatric patients with ALL.
Antitumor T cell responses are neoepitope-specific and form immunodominance hierarchies
In our phenotypic characterization of ALL-specific CD8 + TILs, we observed some patients (e.g., ETV078 and ETV084) with PD-1/ Tim -3-positive CD8 + T cells, the characteristic phenotype of terminal exhaustion. Although our aAPC and functional assays provided clear evidence of tumor-reactive T cells, functional assays poorly detect exhausted cells, which can lead to underestimating the overall response magnitude. Thus, to more precisely quantify the extent to which pediatric ALLs contain a pool of endogenous tumor-reactive CD8 + T cells, we mapped TIL responses to specific epitopes by generating 25 patient-specific tetramers that correspond to the predicted neoepitopes identified previously (table S3) . We used nine unique HLA-A, HLA-B, and HLA-C alleles to accurately assess the global neoantigen-specific CD8 + T cell response in pediatric ALL. Figure 3A shows a representative tetramer gating strategy that was used to identify freshly isolated neoepitope-specific CD8 + TILs. In all six patients, we identified one or more neoepitope-specific CD8 + TIL populations, each of which constituted from 1.1 to 13.4% of the total CD8 + TIL pool (Fig. 3B ). Of the 25 tested patient-specific tetramers, 68% bound to TILs above background set by irrelevant HLAmatched tetramers, indicating that a large proportion of the predicted neoepitopes elicited an endogenous antitumor response from CD8 + T cells (Fig. 3C and fig. S5 ). Within those responses, we observed immunodominance hierarchies among the distinct TIL populations, with a majority of tetramer-bound CD8 + T cells restricted to one or two putative neoepitopes. The tetramer-bound CD8 + T cells recognizing these neoepitopes exhibited both recently activated and chronically activated phenotypes (as defined by PD-1 and Tim-3 expression), further supporting the specificity of these cells for their corresponding neoantigens and suggesting that variable states of differentiation and functionality may exist within neoantigen-specific CD8 + T cells ( fig. S6 ). Together, these results demonstrate that robust CD8 + T cell responses are observable in pediatric leukemias and that a large proportion of potential neoepitopes are targeted by the immune system. Combining the results from the functional and tetramerbinding assays, we find that 86% of the tested neoantigenic peptides and 68% of the generated tetramers elicited a response above background. Using these data to calculate the total number of tumorspecific cells in each patient, we found that the overall magnitude of the CD8 + TIL response in the bone marrow was correlated with the magnitude of the tumor-specific response, suggesting that the antitumor response represents a major component of the TIL population (Spearman's rank correlation  = 0.9429, P = 0.016; Fig. 3D ).
In addition to characterizing the neoantigen-specific CD8 + T cell response against patient-specific somatic missense mutations, we also aimed to establish whether common gene fusions found in pediatric ALL could also be targeted by CD8 + T cells. To this end, we focused on a cohort of patients with a characteristic fusion between ETV6 and RUNX1, which is found in ~20 to 25% of cases of pediatric ALL (42) and is associated with a more favorable prognosis. In our original patient set, we observed ETV6-RUNX1-targeted responses in two of four patients, although the responses were restricted by different HLAs (A*02:01 and B*35:01). We thus selected five more patients for testing, including four with A*02:01 alleles along with several other alleles predicted to bind a fusion-derived peptide. In all five patients, at least one measurable response above background was detected for CD8 + T cells recognizing neoepitopes derived from the ETV6-RUNX1 gene fusion (Fig. 3, E and F) .
Given the degree of antitumor reactivity observed, we designed additional tetramers to test whether the antitumor responses crossreacted with the endogenous, unmutated self-(parent) epitopes. Of the eight parent tetramers that were designed, four failed to fold, likely due to a reduction in peptide:MHC affinity for the parent peptide in comparison to the mutated peptide. However, all four of the folded parent tetramers exhibited reactivity similar to irrelevant background tetramer staining that was lower than the corresponding neoepitope tetramers' reactivity ( fig. S5 ), verifying that the responses detected by our tetramer assays are highly specific for the mutated neoepitopes.
One concern with tetramer-based analyses is the potential for nonspecific binding. Although staining with tetramers containing the parent epitope serves as a strong control for this, we also stained each patient with irrelevant tetramers (designed to match the HLA of the patient) to rule out any inherent staining that results from binding between the patient's TCRs and the tetramer's HLA. The background in each patient to a matched HLA tetramer was consistent with unstained samples, indicating that the high reactivity observed in the tetramer-binding assays did not result from nonspecific binding caused by a patient-intrinsic phenomenon. To rule out potential promiscuous binding from the tetramers that bound high frequencies of cells, we used those tetramers to stain cells from patients with matching HLAs but lacking the mutations associated with the tetramer-specific neoepitopes (table S4) . Again, none of the tetramers showed substantial off-target binding, further demonstrating the specificity of each patient's endogenous CD8 + T cell response toward their corresponding neoepitopes.
Given the broad spread of mean fluorescence intensities observed in tetramers that bound above background, we set out to confirm that cells from the full range of positive staining were specific. We sequenced the paired TCR from 166 PLCD3 tetramer-binding cells from patient ERG009. We observed extensive evidence of clonality, with the top four clonal expansions representing more than 23% of this epitope-specific CD8 + T cell population (Fig. 4A ). Focusing on these four clonal expansions, which represented a range of tetramer-staining intensities (Fig. 4B) , we cloned their TCR. We then stably transduced these receptors by lentiviral transduction into the SUP-T1 cell line and confirmed TCR expression. Each epitope-specific CD8 + TCR clone demonstrated considerable tetramer reactivity (Fig. 4, C to E) . These receptors bound neither the matched HLA parent tetramer containing the unmutated peptide nor the irrelevant tetramer. In addition, the specificity of the mutant tetramer for the cloned TCRs was further supported by the lack of tetramer binding observed within the CCRF-CEM cell line that expressed an irrelevant TCR (Fig. 4, C and E) . Thus, all four cloned receptors, representing 39 cells from the original sort and 23% of the cells binding to this tetramer, were confirmed to be neoepitope specific.
The transcriptional profiles of ALL-specific CD8 + TILs exhibit inter-and intrapatient heterogeneity
The functional and specificity assays indicated that the tumor-specific CD8 + T cells in our samples had a range of intrinsic activities. For example, adding together all the PLCD3 tetramers tested from patient ERG009 resulted in a predicted frequency of about 28% PLCD3-specific cells, and the functional cytokine assay correspondingly indicated a 29% response rate. In contrast, in ETV001 and ETV078, certain epitopes had much higher frequencies associated with tetramer staining than found in the functional assay; for example, the GPR139 tetramer in ETV078 bound to about 14% of the CD8 + T cells, whereas the functional assays only detected about 6% of CD8 + T cells as responsive to the mutated peptide. Hypothesizing that this discordance may be indicative of dysfunction in subsets of these cell populations, we further interrogated the tumor-specific CD8 + T cells via singlecell transcriptional profiling.
To characterize the transcriptional environment of neoepitopespecific TILs, we performed multiplexed quantitative PCR analysis on tetramer-positive and tetramer-negative CD8 + populations; by using an index sorting approach, we were able to simultaneously assay transcription and cell-surface phenotype at single-cell resolution (Fig. 5, A and B, and table S5). Because of the scarcity of material available from the tumor biopsies, this analysis was restricted to the three patients with the greatest number of samples and the highest frequency of tetramer-positive CD8 + T cells. The 88 genes we selected for analysis included transcription factors shown to influence CD8 + T cell differentiation (43), chemokines and chemokine receptors, cytokines, activating and inhibitory co-receptors, and molecules associated with degranulation and cell survival (see Materials and Methods for exclusion criteria and expression-level determination).
To assess the degree of heterogeneity in tumor-specific CD8 + TILs both within and between patients, we focused on the neoepitopespecific effector-phenotype (CCR7 − CD45RO + ) TILs from ERG009, ETV001, and ETV078. The expression of activation markers PD-1 and Tim-3 varied considerably, with ETV078 exhibiting a large proportion of cells with an exhausted phenotype ( fig. S7 ). In line with recent molecular profiling studies (44) (45) (46) , we observed a spectrum of dynamic transcriptional changes that take place during antigenspecific CD8 + T cell responses. We identified three clusters (hierarchical clusters 1 to 3) with distinct transcriptional signatures across the sorted TIL populations, which differed in their functional status and in the expression of transcription factors, transcriptional regulators, signaling inhibitors, cytokines, cytotoxic granules, and trafficking molecules (Fig. 5C) . Specifically, these clusters were distinguished by transcriptional factors and regulators associated with functional effector (TBX21 and EOMES) (43, 47) , dysfunctional (STAT1, STAT3, STAT4, NR4A2, NR4A3, and BCL6) (48, 49) , or exhausted (EOMES, MAF, PRDM1, and BATF) (45, 46) CD8 + T cells. Consistent with published findings (47, 50, 51) , exhausted cells expressed several inhibitory receptors (HAVCR2, LAG3, TIGIT, and CTLA4; Fig. 5C  and fig. S7 ). We observed an exhaustion phenotype (cluster 1) as the majority of tetramer-positive effectors in only a single patient (ETV078), but notably, this patient also exhibited cells that lacked the exhaustion signature (cluster 3). In ETV001, the dominant subset of antigen-specific CD8 + T cells exhibited expression profiles concordant with what has been described elsewhere (48) as a dysfunctional phenotype (cluster 2), characterized by a type I IFN signature. In contrast, most cells from ERG009 exhibited an expression profile corresponding with a classical effector phenotype (GZMB, IFNG, and CXCL10) (43, (52) (53) (54) and lacked exhaustion markers. It has recently been reported that CD8 + T cell differentiation and exhaustion have been coupled to stable changes in DNA methylation programming at loci associated with developmental plasticity and effector function (e.g., TBX21, TCF7, and IFN) (55, 56) . Because our data indicated that many of the neoepitope-specific CD8 + TILs were functional, we tested the methylation profiles for ERG009 and ETV078. Consistent with the effector-like molecular signature we observed for ERG009, we found that the IFN and TBX21 loci for CD45RO + sorted cells from this patient were predominantly unmethylated (Fig. 5D) . In contrast, the CD45RO + GPR139 (297-305) tetramer-sorted cells from ETV078 displayed a more heterogeneous methylation program for the TBX21 locus, which may reflect a greater progression toward an exhaustion phenotype as might be expected given the greater proportion of exhausted cells we observed in this patient compared to ERG009. In addition, the partial demethylation of the TCF7 locus, which has been associated with retention of T cell developmental plasticity (57) , supports the notion that this pool of neoepitope-specific CD8 + TILs may contain cells at various stages of differentiation, including functional effectors. Together, our results demonstrate that pediatric ALL elicits a potent neoepitope-specific CD8 + T cell response that exhibits molecular hallmarks of functional effector differentiation.
DISCUSSION
There are at least three nonmutually exclusive possibilities to explain the much higher response rate in these ALL tumors compared to reports from adult solid tumors. First, it is hypothetically possible that pediatric patients may mount fundamentally different responses compared to adults. Second, hematologic malignancies, and particularly B cell tumors, may be inherently more immunogenic, because they interact with responding T cells as professional immune cells and may therefore provide greater accessibility to infiltrating T cells by not forming a dense epithelial matrix. Last, lower mutation burdens may force the immune response to target most of the potential neoantigens; in the context of a highly diverse epitope landscape, immunodominance effects might drive the response to target a small subset of antigens. Although common mechanisms of immune evasion, such as the down-regulation of specific HLA molecules, might help explain the skewing of the immune response toward a limited number of neoepitopes, we did not find any evidence of selective down-regulation of specific HLA molecules transcriptionally or when staining for the corresponding proteins.
There is some evidence that certain B cell malignancies are highly immunogenic and controllable by T cell responses. Hodgkin's lymphoma, and particularly those with a viral etiology from EBV or HIV, has been shown to be highly responsive to PD-1/PDL1 blockade (58) (59) (60) (61) . In contrast, ICB has shown limited efficacy in other forms of blood cancers, most notably in multiple myeloma (62, 63) . Although responsiveness to checkpoint blockade is not equivalent to immunogenicity in general, the consistent correlation between mutation burden and checkpoint responsiveness has lent support to the idea that mutation burden and immunogenicity are correlated. In the case of ALL, the positive prognosis for standard patients has limited the scope of trials focused on checkpoint blockade. Nonetheless, our data would suggest that the failure of standard checkpoint blockade therapies in ALL is not a consequence of a complete lack of immunogenicity, as we found activated T cells responding to tumor epitopes across every patient. Instead, we suspect that this may be a problem of efficiency, with a relatively low effector:target ratio between the antitumor response and the tumor itself, which has an intrinsically high rate of replication. Furthermore, only a minor portion of the neoepitope-specific T cells we examined exhibited an exhausted phenotype and expression of PD-1; thus, there may not be a clear target for PD-1 checkpoint blockade in this disease context. To fully validate our findings and further address these questions, studies with larger patient cohorts and across multiple institutions would be needed. Recent efforts (64, 65) to identify alternative checkpoints for hematologic malignancies, such as CD200-CD200R, might also explain the lack of antitumor efficacy of these cells.
In addition to identifying antitumor responses for every patient examined, the other notable feature of these experiments was that several mutations within the same patient elicited a T cell response. In some patients, we were able to account for more than 50% of the responsive T cell population in the tumor, although in others, the response rate was much lower. A possible explanation for the reduced response rate is that the rules for peptide binding to certain HLA molecules are incompletely defined owing to the smaller datasets available to train the predictive algorithms used to identify the putative neoepitopes used in our screening assays. Mass spectrometrybased screening approaches could be carried out in tandem to gain a more complete picture of the cancer neoantigens that are processed and presented on tumor cells; however, the large cellular input required for this approach was a limiting factor in our studies. In addition, our focus on fusions and single-nucleotide variant mutations, without consideration of frameshift or indel mutations, may have limited our ability to detect some responses. One possible explanation for the high rate of responsiveness may be immunodominant focusing on the relatively small number of mutations present in the tumor, particularly when compared to adult solid tumors. Immunodominance effects are well defined in viral models of CD8 + T cell responses and have also been increasingly described in human tumors (8) . Immunodominance can create extreme biases, with single, dominant, epitope-targeted T cell populations representing 70 to 80% of the entire CD8 + T cell response to a complex antigen (66) . This remains true even in responses to viruses, where hundreds of potential epitopes are theoretically possible and large numbers of peptides are verifiably processed and presented in infected cells (67, 68) . The parameters that determine immunodominant selection have not been definitively determined, but it is clear that peptide-MHC concentration and T cell precursor frequency are implicated. Tumors with large numbers of mutations and a high potential number of neoepitopes might be akin to a large virus, where only a selected number of epitopes are actually targeted because of this immunodominance effect; relatedly, the immune response may target a greater proportion of potential neoepitopes in tumors with low mutation burden, which is consistent with our observations. Last, determining the heterogeneity of antigen presentation and the extent of inhibitory receptor expression across the tumor will be necessary to assess the extent to which any particular tumor cell is targetable by these effector responses. In support of this idea, we found interesting parallels between the extent of inhibitory receptor ligand expression by tumor cells ( fig. S8 ) and the frequency of exhausted CD8 + T cells (Fig. 5 and fig. S2 ) in our patient samples. Tumors (e.g., ETV078 and ERG016) with increased frequencies of exhausted CD8 + T cells (characterized by high PD-1 and TIM-3 expression) also expressed greater amounts of the corresponding inhibitory ligands (PDL1 and galectin-9, respectively); however, a more in-depth analysis of these factors would be necessary to fully understand their contribution to limiting the immune response. Coculture of purified T cells and tumor cells from the diagnostic sample in two patients over 3 weeks expanded T cells specific for mapped tumor-specific antigens. These data indicate that at least these antigens were actively presented on the ex vivo tumor cells, but the heterogeneity of presentation and the role of cross-presentation in inducing endogenous T cell responses cannot be determined from these experiments. To estimate the heterogeneity in antigen presentation, we used mutant allele frequency value cutoffs established previously (69) to determine the clonality of targeted mutations within our tumor samples. Although our analysis indicated that the mutations were present in most of the ALL blasts and were not subclonal (table S7) , additional single-cell and longitudinal studies would be needed to address questions of clonality and immunoediting definitively. In addition, in vitro or in vivo killing assays with patient-derived xenograft models would help determine the potential potency of these antitumor responses.
Our data provide an opportunity to consider adoptive T cell, monoclonal antibody, and targeted TCR therapy for ALL in pediatric patients. Although ALL currently has a high response rate to traditional chemotherapy approaches, the treatment protocols are extended and induce substantial sequelae. The potential utility of immunotherapies in treating ALL relapse is perhaps even more relevant, because relapse in ALL currently leads to particularly poor prognosis. It is notable that in our study, seven of nine patients with the ETV6-RUNX1 gene fusion generated T cell responses targeting this neoantigen. This raises the possibility of generating off-the-shelf therapeutics that target the primary driver mutation in patients with this and other common fusions. Whereas the public response to these common neoantigens offers more immediate clinical applications, developing a pipeline to rapidly adapt TCRs targeting private neoantigens into therapeutics would be a more generalizable approach for all patients. Although the antitumor T cell responses in these patients did not control their tumors, augmenting antitumor T cell frequencies and providing that enhanced activation signals in the context of transgenic TCR therapy may lead to notable improvements in immune control and should be explored in clinical treatments.
MATERIALS AND METHODS
Study design
The objective of this study was to investigate the response of endogenous CD8 + T cells against patient-specific cancer neoantigens from diagnostic tumor samples collected from pediatric patients with ALL. We hypothesized that although pediatric leukemias contain lower mutational burdens, the neoantigens that arise in this tumor type likely serve as functional targets due to their increased immunogenicity resulting from the tumor's microenvironment, cellular origin, and high neoepitope expression (34) . To test whether endogenous CD8 + TILs were able to effectively recognize and target these mutated neoepitopes directly ex vivo, we monitored TIL degranulation and production of IFN and TNF after stimulation with both aAPCs and autologous tumor cells. We assessed the global neoantigen-specific CD8 + T cell response by mapping TIL responses to specific epitopes using patient-specific tetramers that corresponded to predicted neoepitopes across HLA-A, HLA-B, and HLA-C alleles. We further characterized the nature of the endogenous CD8 + T cell response by determining, at the single cell level, the transcriptional profile of tumor-reactive CD8 + TILs and comparing their inter-and intrapatient heterogeneity. Researchers could not be blinded to experimental procedures due to the nature of the neoantigen screening assays requiring patient-specific neoantigens be used to assess endogenous CD8 + T cell functional responses and due to the limited quantity of material. Pediatric ALL specimens were selected on the basis of sample availability and the cancer type (e.g., B-ALL). The use of human tissues was approved by the institutional review board (IRB #00000029, Expedited Protocol XPD-13-098) of St. Jude Children's Research Hospital. Primary data are reported in data file S1.
Statistical analysis
For single-cell expression data, C t (cycle threshold) values were recovered from the Biomark HD, and data were analyzed using the Fluidigm Real-Time PCR Analysis software. The quality threshold was set to 0.65, and a linear derivative was used for baseline correction. C t values of filtered single-cell expression data were converted to expression thresholds (E t ) and analyzed using the MAST statistical framework (70) in R, which uses hurdle models designed specifically for single-cell expression data that take into account both the proportion of cells expressing a gene and the expression of the gene. Cells with a cellular detection rate in the 1 and 99% quantiles were filtered from further analysis, and missing data points were considered as zero values unless otherwise indicated. Additional statistical methods are described in the figure legends and in the relevant methods descriptions; in general, presented data were largely characterized descriptively without the use of explicit statistical analyses. Hierarchical clustering was performed as described in the "Analysis and visualization of single-cell expression data" section in Supplementary Materials and Methods.
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